Myriad Genetics Inc (Myriad) is a specialty molecular diagnostic company, engaged in the discovery and commercialization of molecular diagnostic tests, and personalized medicine, and provides pharmaceutical and clinical services for major diseases. The company’s product portfolio includes molecular diagnostic testing products that analyze genes, genetic expressions, and corresponding proteins to assess a person’s risk for developing diseases later in life; products related to diagnosis of disease; and determine a patient’s likelihood of responding to a particular drug. Myriad markets its products through sales force in Europe and Canada and distributor agreements in countries in Canada, Middle East, Asia, and Australia. The company has operations in the US, Spain, France, Switzerland, the UK, Canada, Italy, Germany, Japan, Australia, and the Netherlands. Myriad is headquartered in Salt Lake City, Utah, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Myriad Genetics Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Myriad Genetics Inc Company Overview
- Myriad Genetics Inc Company Snapshot
- Myriad Genetics Inc Pipeline Products and Ongoing Clinical Trials Overview
- Myriad Genetics Inc - Pipeline Analysis Overview
- Business Description
- Myriad Genetics Inc - Key Facts
- Myriad Genetics Inc - Major Products and Services
- Myriad Genetics Inc Pipeline Products by Development Stage
- Myriad Genetics Inc Ongoing Clinical Trials by Trial Status
- Myriad Genetics Inc Pipeline Products Overview
- ChemoPredict Test
- ChemoPredict Test Product Overview
- Companion Diagnostic Test - Measurable Residual Disease (MRD)
- Companion Diagnostic Test - Measurable Residual Disease (MRD) Product Overview
- Diagnostic Assay - HER2+/TNBC-Breast Cancer
- Diagnostic Assay - HER2+/TNBC-Breast Cancer Product Overview
- Diagnostic Assay - Juvenile Idiopathic Rheumatoid Arthritis
- Diagnostic Assay - Juvenile Idiopathic Rheumatoid Arthritis Product Overview
- Diagnostic Assay - Lung Cancer
- Diagnostic Assay - Lung Cancer Product Overview
- Diagnostic Assay - Melanoma
- Diagnostic Assay - Melanoma Product Overview
- Diagnostic Assay - Prostate Cancer
- Diagnostic Assay - Prostate Cancer Product Overview
- Diagnostic Test - Colon Cancer
- Diagnostic Test - Colon Cancer Product Overview
- Diagnostic Test - Kidney Damage
- Diagnostic Test - Kidney Damage Product Overview
- FirstGene Comprehensive Prenatal Screen
- FirstGene Comprehensive Prenatal Screen Product Overview
- GeneSight Postpartum Depression Test
- GeneSight Postpartum Depression Test Product Overview
- Genetic Risk Score Test
- Genetic Risk Score Test Product Overview
- Genetic Risk Score Test Clinical Trial
- HRD Companion Diagnostic Test - Breast Cancer
- HRD Companion Diagnostic Test - Breast Cancer Product Overview
- Kidney Transplant Rejection Test
- Kidney Transplant Rejection Test Product Overview
- Lab Developed Test - BRCA Cancer
- Lab Developed Test - BRCA Cancer Product Overview
- Multi-Biomarker Test - Ankylosing Spondylitis
- Multi-Biomarker Test - Ankylosing Spondylitis Product Overview
- Multi-Biomarker Test - Autoimmune Diseases
- Multi-Biomarker Test - Autoimmune Diseases Product Overview
- Multi-Biomarker Test - Inflammatory Diseases
- Multi-Biomarker Test - Inflammatory Diseases Product Overview
- Multi-Biomarker Test - Psoriatic Arthritis
- Multi-Biomarker Test - Psoriatic Arthritis Product Overview
- Multi-Biomarker Test - Systemic Lupus Erythematosus
- Multi-Biomarker Test - Systemic Lupus Erythematosus Product Overview
- myChoice CDx Test - Multiple Cancer
- myChoice CDx Test - Multiple Cancer Product Overview
- myChoice CDx Test - Multiple Cancer Clinical Trial
- myChoice Diabetes
- myChoice Diabetes Product Overview
- myChoice HRD (PARP) - Talazoparib
- myChoice HRD (PARP) - Talazoparib Product Overview
- myPath BiPolar
- myPath BiPolar Product Overview
- myPath Endometriosis
- myPath Endometriosis Product Overview
- myPath Pancreatic Cancer
- myPath Pancreatic Cancer Product Overview
- myPath Prostate Cancer
- myPath Prostate Cancer Product Overview
- myPath Psoriatic Arthritis
- myPath Psoriatic Arthritis Product Overview
- myPlan Renal Cancer Test
- myPlan Renal Cancer Test Product Overview
- myRisk Schizophrenia
- myRisk Schizophrenia Product Overview
- Precise Liquid Bx MRD
- Precise Liquid Bx MRD Product Overview
- Prognostic Test - Bladder Cancer
- Prognostic Test - Bladder Cancer Product Overview
- SanoPredict
- SanoPredict Product Overview
- Tumor BRACAnalysis CDx - Veliparib
- Tumor BRACAnalysis CDx - Veliparib Product Overview
- VeriPsych Test - Bipolar Disorder
- VeriPsych Test - Bipolar Disorder Product Overview
- Whole Exome Companion Diagnostic Test
- Whole Exome Companion Diagnostic Test Product Overview
- Whole Exome Laboratory Developed Test
- Whole Exome Laboratory Developed Test Product Overview
- Myriad Genetics Inc - Key Competitors
- Myriad Genetics Inc - Key Employees
- Myriad Genetics Inc - Key Employee Biographies
- Myriad Genetics Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Myriad Genetics Inc, Recent Developments
- May 03, 2023: Myriad Genetics reports first quarter 2023 financial results
- Dec 19, 2022: Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans
- Oct 31, 2022: Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member
- Jun 23, 2022: Myriad Genetics teams up with Epic to make genetic testing accessible to more patients with Electronic Health Record (EHR) Integration
- Jun 09, 2022: Myriad Genetics CEO Paul Diaz to Speak at Goldman Sachs 43rd Annual Global Healthcare Conference
- May 17, 2022: Shadowbox technology facilitated orders of Myriad Genetics germline diagnostic, increasing volume by more than 800%
- May 04, 2022: Myriad Genetics CEO Paul Diaz to Speak at Bank of America Securities 2022 Healthcare Conference
- Feb 24, 2022: Myriad Genetics Reports Fourth Quarter 2021 Results Provides Updates on Product Performance and Growth Initiatives
- Feb 14, 2022: Myriad Genetics to Present at Two Upcoming Healthcare Conferences
- Jan 04, 2022: Myriad Genetics Chief Scientific Officer Jerry Lanchbury Retires after 19 Years of Service
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Myriad Genetics Inc Pipeline Products and Ongoing Clinical Trials Overview
- Myriad Genetics Inc Pipeline Products by Equipment Type
- Myriad Genetics Inc Pipeline Products by Indication
- Myriad Genetics Inc Ongoing Clinical Trials by Trial Status
- Myriad Genetics Inc, Key Facts
- Myriad Genetics Inc, Major Products and Services
- Myriad Genetics Inc Number of Pipeline Products by Development Stage
- Myriad Genetics Inc Pipeline Products Summary by Development Stage
- Myriad Genetics Inc Ongoing Clinical Trials by Trial Status
- Myriad Genetics Inc Ongoing Clinical Trials Summary
- ChemoPredict Test - Product Status
- ChemoPredict Test - Product Description
- Companion Diagnostic Test - Measurable Residual Disease (MRD) - Product Status
- Companion Diagnostic Test - Measurable Residual Disease (MRD) - Product Description
- Diagnostic Assay - HER2+/TNBC-Breast Cancer - Product Status
- Diagnostic Assay - HER2+/TNBC-Breast Cancer - Product Description
- Diagnostic Assay - Juvenile Idiopathic Rheumatoid Arthritis - Product Status
- Diagnostic Assay - Juvenile Idiopathic Rheumatoid Arthritis - Product Description
- Diagnostic Assay - Lung Cancer - Product Status
- Diagnostic Assay - Lung Cancer - Product Description
- Diagnostic Assay - Melanoma - Product Status
- Diagnostic Assay - Melanoma - Product Description
- Diagnostic Assay - Prostate Cancer - Product Status
- Diagnostic Assay - Prostate Cancer - Product Description
- Diagnostic Test - Colon Cancer - Product Status
- Diagnostic Test - Colon Cancer - Product Description
- Diagnostic Test - Kidney Damage - Product Status
- Diagnostic Test - Kidney Damage - Product Description
- FirstGene Comprehensive Prenatal Screen - Product Status
- FirstGene Comprehensive Prenatal Screen - Product Description
- GeneSight Postpartum Depression Test - Product Status
- GeneSight Postpartum Depression Test - Product Description
- Genetic Risk Score Test - Product Status
- Genetic Risk Score Test - Product Description
- Genetic Risk Score Test - Clinical Trial to Examine Use of Predictive Genetic Tests for Cancer Risks Assessment
- HRD Companion Diagnostic Test - Breast Cancer - Product Status
- HRD Companion Diagnostic Test - Breast Cancer - Product Description
- Kidney Transplant Rejection Test - Product Status
- Kidney Transplant Rejection Test - Product Description
- Lab Developed Test - BRCA Cancer - Product Status
- Lab Developed Test - BRCA Cancer - Product Description
- Multi-Biomarker Test - Ankylosing Spondylitis - Product Status
- Multi-Biomarker Test - Ankylosing Spondylitis - Product Description
- Multi-Biomarker Test - Autoimmune Diseases - Product Status
- Multi-Biomarker Test - Autoimmune Diseases - Product Description
- Multi-Biomarker Test - Inflammatory Diseases - Product Status
- Multi-Biomarker Test - Inflammatory Diseases - Product Descri
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Foundation Medicine Inc
- DNA Diagnostics Center Inc
- Genomind Inc
- Natera Inc
- Exact Sciences Corp
- Quest Diagnostics Inc
- Laboratory Corporation of America
- Ambry Genetics Corp
- InVitae Corp
- Hologic Inc
